Streetbeat News

Products Services

INTC

Intel shares are rising due to reports that the company may receive up to $3.5 billion in funding for US military chip production.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 11:51 am

AMZN

BHP

GOOGL

MSFT

NVDA

TSLA

BHP Group warns of a copper shortage due to increased demand from AI and EV growth, potentially driving prices up. BHP's copper production has risen, and they are investing in new projects to meet future demand. The stock has declined 14% over the past year.

Portfolio Pulse from Anusuya Lahiri

September 16, 2024 | 11:48 am

ITOS

iTeos Therapeutics shares are trading lower following the announcement of follow-up interim data from their GALAXIES Lung-201 study.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 11:40 am

EXAS

Exas Science shares rose following the announcement of positive data for its blood-based colorectal cancer screening test.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 11:37 am

BWAY

BrainsWay is expanding its Deep TMS platform on the East Coast of the U.S. with an order of 14 new systems by a large enterprise network, indicating growth and increased adoption of its technology.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 11:36 am

JAZZ

Jazz Pharmaceuticals released updated data from a Phase 2 trial of Zanidatamab, showing promising results in combination with chemotherapy for treating HER2-expressing advanced or metastatic gastroesophageal adenocarcinoma.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 11:35 am

HYZN

Hyzon Motors has started production of its Class 8 200kW Fuel Cell Electric Truck, marking a significant milestone in collaboration with Fontaine Modification. The company plans to declare SOP on its unique 200kW Fuel Cell System at its Bolingbrook facility soon and aims for ISO 9001 certification by Q4 2024.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 11:34 am

CKPT

Checkpoint Therapeutics presented longer-term data from its pivotal trial of Cosibelimab, an anti-PD-L1 antibody, for treating locally advanced and metastatic cutaneous squamous cell carcinoma at the ESMO Annual Congress.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 11:34 am

CVM

CEL-SCI presented new data from its Phase 3 study of Multikine, showing a 5-year survival rate of 82.6% in certain head and neck cancer patients. This marks the strongest efficacy results for Multikine, suggesting improved outcomes with better patient selection.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 11:32 am

ADEA

Adeia has renewed its intellectual property license agreement with LG Electronics, extending their longstanding relationship. The multi-year agreement covers Adeia's media IP portfolio, including digital video, content discovery, and smart home technologies.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 11:20 am